A laboratory worker prepares messenger RNA (mRNA) at the Inserm ART-RNAm laboratory of the CHR (Regional Hospital Centre), in Orleans, central France, on November 18, 2025. Researchers at Inserm are working to develop new treatments for numerous diseases using messenger RNA, which became widely known to the public through the vaccines developed against COVID-19, particularly to combat pancreatic cancer, one of the most aggressive forms. (Photo by JEAN-FRANCOIS MONIER / AFP) (Photo by JEAN-FRANCOIS MONIER/AFP via Getty Images)

Professor Chantal Pichon speaks at the Inserm ART-RNAm laboratory of the CHR (Regional Hospital Centre), in Orleans, central France, on November 18, 2025. Researchers at Inserm are working to develop new treatments for numerous diseases using messenger RNA, which became widely known to the public through the vaccines developed against COVID-19, particularly to combat pancreatic cancer, one of the most aggressive forms. (Photo by JEAN-FRANCOIS MONIER / AFP) (Photo by JEAN-FRANCOIS MONIER/AFP via Getty Images)

Professor Chantal Pichon speaks at the Inserm ART-RNAm laboratory of the CHR (Regional Hospital Centre), in Orleans, central France, on November 18, 2025. Researchers at Inserm are working to develop new treatments for numerous diseases using messenger RNA, which became widely known to the public through the vaccines developed against COVID-19, particularly to combat pancreatic cancer, one of the most aggressive forms. (Photo by JEAN-FRANCOIS MONIER / AFP) (Photo by JEAN-FRANCOIS MONIER/AFP via Getty Images)

A researcher dilutes messenger RNA (mRNA) at the Inserm ART-RNAm laboratory of the CHR (Regional Hospital Centre), in Orleans, central France, on November 18, 2025. Researchers at Inserm are working to develop new treatments for numerous diseases using messenger RNA, which became widely known to the public through the vaccines developed against COVID-19, particularly to combat pancreatic cancer, one of the most aggressive forms. (Photo by JEAN-FRANCOIS MONIER / AFP) (Photo by JEAN-FRANCOIS MONIER/AFP via Getty Images)

This photograph shows a machine producing large quantities of RNA from yeast at the Inserm ART-RNAm laboratory of the CHR (Regional Hospital Centre), in Orleans, central France, on November 18, 2025. Researchers at Inserm are working to develop new treatments for numerous diseases using messenger RNA, which became widely known to the public through the vaccines developed against COVID-19, particularly to combat pancreatic cancer, one of the most aggressive forms. (Photo by JEAN-FRANCOIS MONIER / AFP) (Photo by JEAN-FRANCOIS MONIER/AFP via Getty Images)

This photograph shows 3D pasta Artisia Salix finger food created by BluRhapsody at the Academia BarillaSi during the Barilla Innovation & Technology Experience (BITE) media day at the Barilla headquarters in Parma, on November 18, 2025. Barilla has invested 20 million in a research and development center (Barilla Innovation & Technology Experience - BITE) employing 200 people, which aims to solidify the group's position among the giants of "Made in Italy", marking the company's most significant investment in food innovation in recent years. (Photo by Stefano RELLANDINI / AFP) (Photo by STEFANO RELLANDINI/AFP via Getty Images)

This photograph shows spaghetti pasta on the production line of the Barilla factory during the Barilla Innovation & Technology Experience (BITE) media day at the Barilla haedquater in Parma, on November 18, 2025. Barilla has invested 20 million in a research and development center (Barilla Innovation & Technology Experience - BITE) employing 200 people, which aims to solidify the group's position among the giants of "Made in Italy", marking the company's most significant investment in food innovation in recent years. (Photo by Stefano RELLANDINI / AFP) (Photo by STEFANO RELLANDINI/AFP via Getty Images)

President of Barilla Group, the world's largest pasta company, Guido Barilla, looks on during the Barilla Innovation & Technology Experience (BITE) media day at the Barilla headquarters in Parma, on November 18, 2025. Barilla has invested 20 million in a research and development center (Barilla Innovation & Technology Experience - BITE) employing 200 people, which aims to solidify the group's position among the giants of "Made in Italy", marking the company's most significant investment in food innovation in recent years. (Photo by Stefano RELLANDINI / AFP) (Photo by STEFANO RELLANDINI/AFP via Getty Images)